Advertisement

Topics

After MYSTIC setback, FDA gives some comfort to AZ

06:33 EDT 31 Jul 2017 | PMLIVE

Awards its PD-L1 inhibitor Imfinzi breakthrough status in locally-advanced NSCLC

Original Article: After MYSTIC setback, FDA gives some comfort to AZ

NEXT ARTICLE

More From BioPortfolio on "After MYSTIC setback, FDA gives some comfort to AZ"

Quick Search
Advertisement
 

Relevant Topic

Gilotrif (afatinib)
GILOTRIF (afatinib) is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L8...